Adial Pharmaceuticals Inc.
ADIL | NASDAQ
$4.40
-$0.46 (-9.47%)
At close: Sep 21, 2026, 4:00 PM ET
$4.48
+$0.08 (+1.82%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 564 | n/a | n/a | 564 |
Gross Profit | n/a | n/a | -564 | n/a | n/a | -564 |
Operating Income | -7.8M | -8.28M | -6.89M | -10.86M | -19.29M | -10.93M |
Interest Income | 149.57K | 178.66K | 69.78K | 63.34K | 6.54K | 32.5K |
Pretax Income | -7.98M | -13.2M | -7M | -10.8M | -19.52M | -10.89M |
Net Income | -7.98M | -13.2M | -7M | -12.73M | -19.42M | -10.86M |
Selling & General & Admin | 5.18M | 5.06M | 5.62M | 8.91M | 9.34M | 5.07M |
Research & Development | 2.62M | 3.23M | 1.27M | 1.95M | 8.4M | 5.85M |
Other Expenses | n/a | n/a | -564 | n/a | 1.55M | n/a |
Operating Expenses | 7.8M | 8.28M | 6.89M | 10.86M | 19.29M | 10.93M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 7.8M | 8.28M | 6.89M | 10.86M | 19.29M | 10.93M |
Income Tax Expense | n/a | n/a | n/a | n/a | -94.08K | -32.5K |
Shares Outstanding (Basic) | 668.63K | 743.55K | 56.99K | 42.52K | 29.74K | 19.94K |
Shares Outstanding (Diluted) | 668.63K | 743.55K | 56.99K | 42.52K | 29.74K | 19.94K |
EPS (Basic) | -11.93 | -17.75 | -136 | -299.50 | -653 | -544.75 |
EPS (Diluted) | -11.93 | -17.75 | -136 | -299.50 | -653 | -544.75 |
EBITDA | -7.98M | -13.2M | -7M | -10.8M | -17.69M | -10.93M |
EBIT | -7.98M | -13.2M | -7M | -10.8M | -17.74M | -10.89M |
Depreciation & Amortization | 565 | 565 | 564 | 564 | 55.11K | 564 |
Add to Watchlist
Select watchlists to add or remove ADIL